These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23109445)

  • 1. Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment.
    Venegas M; Brahm J; Villanueva RA
    Ann Hepatol; 2012; 11(6):827-37. PubMed ID: 23109445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL28B polymorphism -- predictive factor of HCV infected genotype 1 individuals to treatment response and management of therapy.
    Ioniţă-Radu F; Raşcanu A; Cheiab B
    Rom J Intern Med; 2011; 49(2):99-104. PubMed ID: 22303600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
    Sticchi L; Di Biagio A; Sartini M; Rappazzo E; Nicolini LA; Cenderello G; Valle C; Azzola E; Grasso A; De Leo P; Boldrini A; Setti M; Prinapori R; Lorusso C; Bruzzone B; Icardi G;
    New Microbiol; 2015 Oct; 38(4):499-509. PubMed ID: 26485009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors that predict response of patients with hepatitis C virus infection to boceprevir.
    Poordad F; Bronowicki JP; Gordon SC; Zeuzem S; Jacobson IM; Sulkowski MS; Poynard T; Morgan TR; Molony C; Pedicone LD; Sings HL; Burroughs MH; Sniukiene V; Boparai N; Goteti VS; Brass CA; Albrecht JK; Bacon BR;
    Gastroenterology; 2012 Sep; 143(3):608-618.e5. PubMed ID: 22626609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D pathway gene variants and HCV-2/3 therapy outcomes.
    Cusato J; Allegra S; Boglione L; De Nicolò A; Baietto L; Cariti G; Di Perri G; D'Avolio A
    Antivir Ther; 2015; 20(3):335-41. PubMed ID: 25279449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
    Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice.
    Chen R; Kobewka M; Addison W; Lachance G; Tyrrell DL
    PLoS One; 2016; 11(1):e0147007. PubMed ID: 26765841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients.
    Tsubota A; Shimada N; Yoshizawa K; Furihata T; Agata R; Yumoto Y; Abe H; Ika M; Namiki Y; Chiba K; Fujise K; Tada N; Aizawa Y
    Liver Int; 2012 May; 32(5):826-36. PubMed ID: 22212648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study.
    Kamal SM; Kassim SK; Ahmed AI; Mahmoud S; Bahnasy KA; Hafez TA; Aziz IA; Fathelbab IF; Mansour HM
    Am J Gastroenterol; 2014 Feb; 109(2):199-211. PubMed ID: 24445571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients.
    Mangia A
    Liver Int; 2011 Jan; 31(1):36-41. PubMed ID: 21040409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
    Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
    Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
    Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care.
    McHutchison JG
    Liver Int; 2011 Jan; 31 Suppl 1():29-35. PubMed ID: 21205135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redefining baseline demographics: the role of genetic testing in hepatitis C virus infection.
    Holmes JA; Desmond PV; Thompson AJ
    Clin Liver Dis; 2011 Aug; 15(3):497-513. PubMed ID: 21867933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 28B polymorphisms and therapy response in Egyptian hepatitis C genotype-4 patients.
    Gouda HM; El-Saadany ZA; Foad NB; Salama RM
    DNA Cell Biol; 2014 Sep; 33(9):642-6. PubMed ID: 24999753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of non-genotype 1 hepatitis C virus patients.
    Mangia A; Mottola L
    Curr Gastroenterol Rep; 2012 Feb; 14(1):87-93. PubMed ID: 22113745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan.
    Zia A; Ali M; Aziz H; Zia M; Shinwari ZK; Raza A
    Infect Dis Poverty; 2018 Feb; 7(1):11. PubMed ID: 29429413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.
    Rivero-Juarez A; Camacho A; Caruz A; Neukam K; Gonzalez R; Di Lello FA; Perez-Camacho I; Mesa P; Torre-Cisneros J; Peña J; Pineda JA; Rivero A
    AIDS; 2012 May; 26(8):1009-15. PubMed ID: 22382144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.